Nimotuzumab on ASCO 2022
Oncoscience | June 7th, 2022
Once again, Nimotuzumab’s efficacy and safety in several cancer types were discussed and analyzed thorou...
Webinar – The Role of Nimotuzumab in the Treatment of Head and Neck and Nasopharyngeal Cancer
Oncoscience | May 28th, 2022
This webinar was conducted on May 28th, 2022 discussing the role of Nimotuzumab in the treatment of locall...
Specific Pharma A/S and Oncoscience GmbH launch a Named Patient Program for the treatment of cancer with nimotuzumab.
Oncoscience | November 6th, 2020
Specific Pharma announced today that it has entered into a supply and distribution collaboration with German based Onc...
Children with diffuse intrinsic pons glioma (DIPG) benefit from nimotuzumab
Oncoscience | March 25th, 2019
The results of an international clinical trial were published in March 2019. Forty-two children aged 3 to 20 years suffe...
Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher® (Nimotuzumab) in the U.K. and Ireland
Oncoscience | October 3rd, 2018
Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingd...